amrubicin

Amrubicin is a third-generation synthetic anthracycline and topoisomerase II inhibitor used primarily in the treatment of lung cancer, including both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)[1][2][4][6]. It acts as a prodrug, being converted in vivo to its active metabolite, amrubicinol, which is significantly more potent. The drug exerts its antineoplastic effects by intercalating into DNA and stabilizing the DNA-topoisomerase II complex, thereby inhibiting DNA replication and transcription, leading to cell cycle arrest at the G2/M phase and ultimately inducing apoptosis[1][2][3][5]. Amrubicin was first developed by Sumitomo (now Sumitomo Pharma) and has been marketed in Japan since 2002 under the brand name Calsed[4]. It is administered intravenously. Unlike other anthracyclines such as doxorubicin, it demonstrates less cardiac toxicity while maintaining strong anti-tumor activity[1].

Brand names

Calsed

Other names

amrubicinaamrubicineAmrubicin [INN]